A Retrospective Study Of Pemetrexed In The Treatment Of Elderly Patients With Lung Adenocarcinoma

Objective:To retrospectively analyze the efficacy and toxicity of pemetrexed contrast to the best supportive care in the elderly patients with lung adenocarcinoma.Methods:This is a retrospective study including 88 elderly patients of adenocarcinoma of the lung, ECOG≤2 and older than 65. They were divided into the research group (n=44) and the control group with the best supportive care (n=44) depending on whether the application of chemotherapy with pemetrexed. The study group accepted pemetrexed+/- cisplatin (monotherapy group 19 cases, combined group 25 cases),500 mg/m2, every 21 days as a cycle. Dexamethasone, folic acid and vitamin B12 were applied to relieve the adverse reactions. The curative effect and adverse reactions were assessed after two or four therapeutic cycles for the research group; the control group was evaluated after 2 months.Results:In the research group there were 1 patients of CR(2.2%),12 patients of PR (27.3%),19 patients of NC (43.2%) and 13 patients of PD (27.3%), the effective rate(CR+PR) was 29.6%, and the monotherapy group effective rate(CR+PR) was 26.3%. In the control group, there were 0 patients of CR,0 patients of PR,15 patients of NC (34.1%) and 29 patients of PD (65.9%), with 5 patients of death, the effective rate(CR+PR) was 0. In the research group there were 2 patients with Ⅲ grad bone marrow suppression, and in the control group, there were 1 patient with Ⅲ gastrointestinal toxicity, and there was no IV grade adverse effects in all the patients.Conclusion:The pemetrexed group contrast to the best supportive care has better treatment effect and adverse reaction in patients of ECOG≤2 and older than 65 with adenocarcinoma of the lung, and the toxicity could be tolerated.